According to sources, Meridian Bioscience has received approval by the FDA for its test, TRU Legionella, which can detect Legionnaires’ disease. The diagnostic distinguishes Legionella pneumophila serogroup 1, which commonly leads to Legionnaires’ disease amongst those who contract the bacteria. The test has the ability to expedite detection of bacteria, leading to faster diagnoses and treatment of the disease. Legionnaires’ disease is believed to be an under-diagnosed illness, and only accounts for 5-8% of the 4-5 million pneumonia cases each year in the U.S. Meridian believes TRU Legionella will lead to increased diagnoses of Legionnaires’ disease, once the test begins to be utilized by hospitals and researchers. This may be an important development and updates will be posted as soon as they become available.
For additional information, please see the following articles: